Senior Director, Health Economics and Outcomes Research

Job Summary

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small‑molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first‑in‑class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody‑drug conjugates (ADCs) for molecularly defined solid‑tumor indications.

Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

South San Francisco, CA.

We are seeking a Senior Director of Health Economics and Outcomes Research / Real World Evidence (HEOR/RWE) to join the IDEAYA Commercial team. The Senior Director, HEOR/RWE will shape and execute IDEAYA’s health economics, outcomes research, and real‑world evidence strategy for the launch of darovasertib in metastatic uveal melanoma (mUM). This leader will play a pivotal role in generating evidence in a very high unmet disease area for payers, providers, and patients, and will take innovative approaches to value demonstration in orphan diseases, biomarker‑driven populations, and unique combination treatments.

While the initial focus will be on darovasertib, this role will evolve over time to include direct reports and contribute on the global launches of IDEAYA’s exciting pipeline of oncology assets. The position is based in our South San Francisco headquarters and requires onsite presence four days per week.

• Develop and execute the HEOR and RWE strategy to support US value demonstration for darovasertib at launch and through its lifecycle.
• Collaborate with Market Access, Medical Affairs and Clinical Development to evaluate data gaps and develop robust evidence generation and publication plans.
• Develop and execute core evidence‑generation activities including chart reviews, literature reviews, PRO studies, and micro‑costing analyses to strengthen the clinical and economic differentiation of the product.
• Design and implement real‑world data analyses to articulate the current patient demographics, treatment patterns, and outcomes for mUM patients.
• Develop comprehensive health economic model analyses to demonstrate value, inform pricing strategy, and support reimbursement decisions.
• Partner with Market Access to develop robust and compelling clinical, humanistic, and economic value propositions and oversee development of AMCP and Global Value Dossiers.
• Lead the external dissemination of HEOR/RWE deliverables including publications, presentations, and professional conferences.
• Develop, train, and implement the resources that support field HEOR efforts with key customers; ensure programs and materials comply with SOPs and Medical, Legal & Regulatory (MLR) reviews.
• Engage and collaborate with external partners including payers, providers, and other access decision‑makers to establish and maintain strong partnerships and gather insights.
• Support field team engagements during Preapproval Information Exchange (PIE) and post‑approval interactions to educate payers and provider access stakeholders on darovasertib.
• Stay current with advancements in methodologies and best practices; closely monitor new trends in health policy and payer environment and integrate into cross‑functional strategies.
• Influence the design of IDEAYA’s clinical development programs through global price and market access and commercial opportunity assessments.
• Oversee budgeting and financial planning for all HEOR/RWE activities.

• Advanced, doctoral level degree in a related discipline with at least 10–15 years of related experience.
• Experience in the biotech/pharmaceutical industry in US HEOR/RWE and with market access strategies.
• Experience with rare disease and oral drugs is strongly preferred.
• Demonstrat…